Systematic (IUPAC) name
3-(3,4-Diphenyl- 1H-pyrazol- 1-yl)- N,N-dimethylpropan- 1-amine
Clinical data
Legal status
  • Uncontrolled
Routes Oral
CAS number
ATC code None
Chemical data
Formula C20H23N3 
Mol. mass 305.42 g/mol

Fezolamine (Win-41,528-2) is a drug which was investigated by Sterling Drug as an antidepressant in the 1980s.[1][2] The isomeric N,N-dimethyl-4,5-diphenyl-1H-pyrazole-1-propanamine was completely inactive in the primary antidepressant screens.

It acts as a serotonin, norepinephrine, and dopamine reuptake inhibitor, with 3- to 4-fold preference for the former neurotransmitter.[3] It was found to be effective and well tolerated in clinical trials but was never marketed.[4]

See also


  1. ^ U.S. Patent 4,182,895
  2. ^ Bailey, D. M.; Hansen, P. E.; Hlavac, A. G.; Baizman, E. R.; Pearl, J.; Defelice, A. F.; Feigenson, M. E. (1985). "3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants". Journal of Medicinal Chemistry 28 (2): 256–60.  
  3. ^ Baizman, E. R.; Ezrin, A. M.; Ferrari, R. A.; Luttinger, D (1987). "Pharmacologic profile of fezolamine fumarate: A nontricyclic antidepressant in animal models". The Journal of pharmacology and experimental therapeutics 243 (1): 40–54.  
  4. ^ Zisook, S.; Mendels, J.; Janowsky, D.; Feighner, J.; Lee, J. C. M.; Fritz, A. (1987). "Efficacy and Safety of Fezolamine in Depressed Patients". Neuropsychobiology 17 (3): 133–8.